We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Applied Biosystems Announce Global Commercialization of Applied Biosystems 3500 Series Genetic Analyzers
News

Applied Biosystems Announce Global Commercialization of Applied Biosystems 3500 Series Genetic Analyzers

Applied Biosystems Announce Global Commercialization of Applied Biosystems 3500 Series Genetic Analyzers
News

Applied Biosystems Announce Global Commercialization of Applied Biosystems 3500 Series Genetic Analyzers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Applied Biosystems Announce Global Commercialization of Applied Biosystems 3500 Series Genetic Analyzers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Applied Biosystems, part of Life Technologies Corporation has announced the global commercial availability of a new capillary electrophoresis (CE) sequencing system.

The 3500 Series Genetic Analyzer builds on Applied Biosystems’ CE sequencing systems, with advancements, setting significant new standards for throughput, data quality. The 3500 Series Genetic Analyzer is for research use only not intended for therapeutic or diagnostic use.

Since May 2009, more than 10 research institutions have been participating in an early evaluation of the technology with primary interest in studying the most widely recognized human genetic disorders, such as those caused by extra or missing chromosomes, as well as a broad spectrum of other diseases.

Some of the global research institutions participating in the early evaluation program are the Peter MacCallum Cancer Centre, Australia; Massachusetts General Hospital, USA; Institute Paoli Calmette, France; University College London Hospital, United Kingdom; Silvestrini Hospital Molecular, Italy; Laboratório de Genômica e Biologia Molecular, Centro de Pesquisa – Hospital A. C. Camargo, Brazil; Transcriptome Research Group, National Institute of Radiological Sciences, Japan; and University of Tokyo, Japan.

The 3500 Series enables researchers to run up to 1,100 sequencing or 1,200 genotyping samples per day. It features consumable designs that incorporate the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal systems designs, and redesigned data collection and analysis software.

Dr. Iafrate and his team are using Applied Biosystems CE technology in a variety of pre-clinical studies to investigate potential correlations between genetic mutations and the formation of disease, including cancer. The range of research tests using CE technology include microsatellite instability analyses, sequencing, and higher-throughput genotyping of various cancer tissues to aid cancer research.
Advertisement